Its losses have been rising in recent years as has its share count -- a notable concern for investors. 10 stocks we like ...

An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 5.7% in that time frame, underperforming the S&P 500. Will the recent positive ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...